AI company Sensyne Health plc has appointed Dr David Ruau as chief scientific officer, a newly created role, with effect from 1 September 2021.
He will lead the research effort at Sensyne aimed at applying ethical AI to the improvement of patient care and the discovery and development of new medicines.
Ruau has experience with the application of big data and AI to pharmaceutical research & development and joins Sensyne from Bayer Pharmaceuticals where, from 2017, he was head of global data assets and decision science. In this role, he led teams working on the development and application of AI solutions in oncology, radiology and women’s health. Prior to joining Bayer, he was head of scientific computing solutions at AstraZeneca.
Sensyne CEO Lord (Paul) Drayson said: ‘With his wealth of experience in bioinformatics, pharma and data science, I am delighted to welcome David to Sensyne. His experience will be invaluable as we continue to innovate and develop our work applying ethical AI to improve patient care and to accelerate the development of new medicines.’
Ruau said: ‘I am thrilled to be joining Sensyne at such an exciting time for the business and for the pharmaceutical AI sector. The ethical application of AI to improve healthcare for patients and life sciences research is one of my greatest passions. Sensyne has a unique model that offers the potential to transform pharmaceutical development and I am greatly looking forward to joining the team.’